Incidence and prevalence of juvenile idiopathic arthritis among children in a managed care population, 1996-2009
- PMID: 23588938
- PMCID: PMC5657479
- DOI: 10.3899/jrheum.120661
Incidence and prevalence of juvenile idiopathic arthritis among children in a managed care population, 1996-2009
Abstract
Objective: Few studies based in well-defined North American populations have examined the occurrence of juvenile idiopathic arthritis (JIA), and none has been based in an ethnically diverse population. We used computerized healthcare information from the Kaiser Permanente Northern California membership to validate JIA diagnoses and estimate the incidence and prevalence of the disease in this well-characterized population.
Methods: We identified children aged ≤ 15 years with ≥ 1 relevant International Classification of Diseases, 9th edition, diagnosis code of 696.0, 714, or 720 in computerized clinical encounter data during 1996-2009. In a random sample, we then reviewed the medical records to confirm the diagnosis and diagnosis date and to identify the best-performing case-finding algorithms. Finally, we used the case-finding algorithms to estimate the incidence rate and point prevalence of JIA.
Results: A diagnosis of JIA was confirmed in 69% of individuals with at least 1 relevant code. Forty-five percent were newly diagnosed during the study period. The age- and sex-standardized incidence rate of JIA per 100,000 person-years was 11.9 (95% CI 10.9-12.9). It was 16.4 (95% CI 14.6-18.1) in girls and 7.7 (95% CI 6.5-8.9) in boys. The peak incidence rate occurred in children aged 11-15 years. The prevalence of JIA per 100,000 persons was 44.7 (95% CI 39.1-50.2) on December 31, 2009.
Conclusion: The incidence rate of JIA observed in the Kaiser Permanente population, 1996-2009, was similar to that reported in Rochester, Minnesota, USA, but 2 to 3 times higher than Canadian estimates.
Keywords: COMPUTERIZED MEDICAL INFORMATION; EPIDEMIOLOGY; HEALTH MAINTENANCE ORGANIZATIONS; INCIDENCE; JUVENILE IDIOPATHIC ARTHRITIS; PREVALENCE.
Figures
Similar articles
-
Juvenile Idiopathic Arthritis in Olmsted County, Minnesota, 1960-2013.Arthritis Rheumatol. 2016 Jan;68(1):247-54. doi: 10.1002/art.39323. Arthritis Rheumatol. 2016. PMID: 26316119 Free PMC article.
-
Epidemiology of rheumatoid arthritis, juvenile idiopathic arthritis and gout in two regions of the Czech Republic in a descriptive population-based survey in 2002-2003.Clin Exp Rheumatol. 2006 Sep-Oct;24(5):499-507. Clin Exp Rheumatol. 2006. PMID: 17181917
-
Trends in Population-Based Incidence and Prevalence of Juvenile Idiopathic Arthritis in Manitoba, Canada.Arthritis Care Res (Hoboken). 2019 Mar;71(3):413-418. doi: 10.1002/acr.23606. Epub 2019 Feb 4. Arthritis Care Res (Hoboken). 2019. PMID: 29799673
-
Epidemiology and demographics of juvenile idiopathic arthritis in Africa and Middle East.Pediatr Rheumatol Online J. 2021 Dec 2;19(1):166. doi: 10.1186/s12969-021-00650-x. Pediatr Rheumatol Online J. 2021. PMID: 34857004 Free PMC article. Review.
-
Prevalence and incidence of juvenile idiopathic arthritis: a systematic review.Joint Bone Spine. 2014 Mar;81(2):112-7. doi: 10.1016/j.jbspin.2013.09.003. Epub 2013 Nov 6. Joint Bone Spine. 2014. PMID: 24210707 Review.
Cited by
-
Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective.J Manag Care Spec Pharm. 2024 Nov;30(11):1226-1238. doi: 10.18553/jmcp.2024.24036. Epub 2024 Jul 27. J Manag Care Spec Pharm. 2024. PMID: 39066551 Free PMC article.
-
Real-World Health Care Outcomes and Costs Among Patients With Juvenile Idiopathic Arthritis in Spain.J Health Econ Outcomes Res. 2023 Dec 20;10(2):141-149. doi: 10.36469/001c.85088. eCollection 2023. J Health Econ Outcomes Res. 2023. PMID: 38145114 Free PMC article.
-
Bayesian causal inference for observational studies with missingness in covariates and outcomes.Biometrics. 2023 Dec;79(4):3624-3636. doi: 10.1111/biom.13918. Epub 2023 Aug 8. Biometrics. 2023. PMID: 37553770
-
The effect of TNF treatment uptake on incident hospital admission in Western Australia.Pediatr Rheumatol Online J. 2023 Mar 28;21(1):29. doi: 10.1186/s12969-023-00810-1. Pediatr Rheumatol Online J. 2023. PMID: 36973788 Free PMC article.
-
Efficacy and safety of TNF inhibitors in the treatment of juvenile idiopathic arthritis: a systematic literature review.Pediatr Rheumatol Online J. 2023 Feb 24;21(1):20. doi: 10.1186/s12969-023-00798-8. Pediatr Rheumatol Online J. 2023. PMID: 36829225 Free PMC article.
References
-
- Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369:767–78. - PubMed
-
- Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–2. - PubMed
-
- Nordal E, Zak M, Aalto K, Berntson L, Fasth A, Herlin T, et al. Ongoing disease activity and changing categories in a long-term Nordic cohort study of juvenile idiopathic arthritis. Arthritis Rheum. 2011;63:2809–18. - PubMed
-
- Simon D. Management of growth retardation in juvenile idiopathic arthritis. Horm Res. 2007;68(Suppl 5):122–5. - PubMed
-
- Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63:465–82. - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical